

Renal and Extrarenal Phenotypes in Patients With *HNF1B* Variants and Chromosome 17q12 Microdeletions



Bénédicte Buffin-Meyer^{1,2,56,57}, Juliette Richard^{3,4,56}, Vincent Guignon^{5,57}, Stefanie Weber^{6,57,58}, Jens König^{7,57,58}, Laurence Heidet^{8,9,57}, Nabila Moussaoui^{1,4,10,57}, Jeanne-Pierrette Vu^{1,2}, Stanislas Faguer^{1,2,4,11,57}, Audrey Casemayou^{1,2,4,11}, Richa Prakash^{8,9,57}, Véronique Baudouin^{12,57}, Julien Hogan^{12,57}, Demi Alexandrou¹³, Detlef Bockenhauer^{14,15,16,57}, Justine Bacchetta^{17,18,57}, Bruno Ranchin^{17,57}, Stepanka Pruhova¹⁹, Jakub Zieg^{19,57}, Annie Lahoche²⁰, Christine Okorn^{21,57,58}, Violetta Antal-Kónya^{22,23}, Denis Morin^{24,25,26,57}, Francesca Becherucci^{27,57}, Sandra Habbig^{28,57,58}, Max C. Liebau^{29,57,58}, Mathilde Maura^{30,57}, Tom Nijenhuis^{31,57}, Brigitte Llanas^{32,57}, Djalila Mekahli^{33,34,57}, Julia Thumfart^{35,57,58}, Burkhard Tönshoff^{36,57,58}, Laura Massella^{37,57}, Philippe Eckart³⁸, Sylvie Cloarec^{39,40}, Alejandro Cruz^{41,57}, Ludwig Patzer^{42,58}, Gwenaelle Roussey^{43,44}, Isabelle Vrillon⁴⁵, Olivier Dunand⁴⁶, Lucie Bessenay⁴⁷, Francesca Taroni^{48,57}, Marcin Zaniew^{49,58}, Ferialle Louillet⁵⁰, Carsten Bergmann^{51,52}, Franz Schaefer^{53,57}, Albertien M. van Eerde^{54,57}, Joost P. Schanstra^{1,2,57} and Stéphane Decramer^{1,3,4,57}, on behalf of the HNF1B variant study group⁵⁵

¹National Institute of Health and Medical Research (INSERM), UMR 1297, Institute of Cardiovascular and Metabolic Disease, Toulouse, France; ²University Paul Sabatier, Toulouse-III, Toulouse, France; ³Department of Pediatric Internal Medicine, Rheumatology and Nephrology, Toulouse University Hospital, Toulouse, France; ⁴Centre De Référence Des Maladies Rénales Rares du Sud-Ouest (SORARE), Toulouse University Hospital, Toulouse, France; ⁵Department of Pediatrics, Hôpital Mère-Enfant, University Hospital of Limoges, Limoges, France; ⁶Pediatric Nephrology, University Children's Hospital Marburg, Marburg, Germany; ⁷Department of General Pediatrics, University Children's Hospital, Münster, Germany; ⁸APHP, Service de Néphrologie Pédiatrique, Hôpital Universitaire Necker-Enfants malades, Paris, France; ⁹Centre De Référence Des Maladies Rénales Héritaires de l'Enfant et de l'Adulte (MARHEA), Paris, France; ¹⁰Filière ORphan Kidney Disease (ORKiD), Montpellier, France; ¹¹Department of Nephrology and Organ Transplantation, University Hospital of Toulouse, and French Intensive Care Renal Network, Toulouse, France; ¹²Nephrology Department, Robert Debré Hospital, APHP Nord, Paris University, Paris, France; ¹³University College London Medical School, London, UK; ¹⁴University College London, Department of Renal Medicine, London, UK; ¹⁵Renal Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; ¹⁶Department of Pediatric Nephrology, University Hospitals Leuven, Leuven, Belgium; ¹⁷Centre de Référence des Maladies Rénales Rares, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France; ¹⁸INSERM 1033, Faculté de Médecine Lyon Est, Lyon, France; ¹⁹Department of Pediatrics, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic; ²⁰Unité de néphrologie, Hôpital Jeanne de Flandre, CHU Lille, Lille, France; ²¹Department of Pediatrics II, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany; ²²MTA-SE Lendület Nephrogenetic Laboratory, Budapest, Hungary; ²³Department of Pediatrics, Semmelweis University, Budapest, Hungary; ²⁴Néphrologie Pédiatrique, CHU de Montpellier, Montpellier, France; ²⁵Centre De Référence Des Maladies Rénales Rares du Sud-Ouest (SORARE), Montpellier, France; ²⁶Université de Montpellier, Montpellier, France; ²⁷Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy; ²⁸Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; ²⁹Department of Pediatrics and Center for Family Health, Center for Rare Diseases and Center for Molecular Medicine, University Hospital Cologne and Medical Faculty, University of Cologne, Cologne, Germany; ³⁰Department of Pediatrics, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, France; ³¹Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands; ³²Unité de Néphrologie Pédiatrique, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Centre de Références des Maladies rénales rares du Sud-Ouest (SORARE), Bordeaux, France; ³³Department of Pediatric Nephrology,

Correspondence: Stéphane Decramer, Department of Pediatric Internal Medicine, Rheumatology and Nephrology, Toulouse University Hospital, Toulouse, France. E-mail: decramer.s@chu-toulouse.fr; or Joost P. Schanstra, National Institute of Health and Medical Research (INSERM), UMR 1297, Institute of Cardiovascular and Metabolic Disease, Toulouse, France. E-mail: Joost-peter.schanstra@inserm.fr

⁵⁵Members of *HNF1B* variant study group are listed in the Appendix.

⁵⁶BB-M and JR had equal contribution.

⁵⁷Member of the ERKNet network.

⁵⁸Member of the Neocyst consortium.

Received 13 February 2024; revised 9 April 2024; accepted 6 May 2024; published online 16 May 2024

University Hospitals, Leuven, Belgium; ³⁴PKD Research Group, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium; ³⁵Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Berlin, Germany; ³⁶Department of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany; ³⁷Division of Nephrology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; ³⁸Department of Pediatrics, University Hospital of Caen, Caen, France; ³⁹Service de Néphrologie Pédiatrique, Hôpital Clocheville, CHRU, Tours, France; ⁴⁰Centre De Compétence Maladies Rénales Rares, Filière ORphan Kidney Disease (ORKiD), France; ⁴¹Pediatric Nephrology, University Hospital Vall d'Hebron, Barcelona, Spain; ⁴²Klinik für Kinder- und Jugendmedizin, Krankenhaus St. Elisabeth und St. Barbara, Halle/Saale, Germany; ⁴³Service des Maladies Chroniques de l'Enfant, Hôpital Mère Enfant, CHU Nantes, Nantes, France; ⁴⁴Centre De Référence Des Maladies Rénales Rares du Sud-Ouest (SORARE), Nantes, France; ⁴⁵Service de Néphrologie Pédiatrique, Hôpital des Enfants, CHRU Nancy, Vandoeuvre les Nancy, France; ⁴⁶Service de Néphrologie Pédiatrique, CHU Réunion site Félix GUYON, St Denis, Ile de La Réunion, France; ⁴⁷Department of Pediatric Nephrology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France; ⁴⁸Pediatric Nephrology, Dialysis and Transplantation Unit Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy; ⁴⁹Department of Pediatrics, University of Zielona Góra, Zielona Góra, Poland; ⁵⁰Département de Pédiatrie, Unité de Néphrologie-Hémodialyse, CHU Charles Nicolle, Rouen, France; ⁵¹Medizinische Genetik Mainz, Limbach Genetics, Mainz, Germany; ⁵²Department of Medicine IV, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany; ⁵³Division of Pediatric Nephrology, Heidelberg University Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany; and ⁵⁴Department of Genetics, UMC Utrecht, Utrecht, The Netherlands

Introduction: Hepatocyte nuclear factor 1-beta (*HNF1B*) gene variants or the chromosome 17q12 deletion (17q12del) represent the most common monogenic cause of developmental kidney disease. Although neurodevelopmental disorders have been associated with the 17q12del, specific genotype-phenotype associations with respect to kidney function evolution have not yet been fully defined. Here, we aimed to determine whether 17q12del or specific *HNF1B* variants were associated with kidney survival in a large patient population with *HNF1B* disease.

Methods: This was a retrospective observational study involving 521 patients with *HNF1B* disease from 14 countries using the European Reference Network for rare kidney diseases with detailed information on the *HNF1B* genotype (*HNF1B* variants or the 17q12del). Median follow-up time was 11 years with 6 visits per patient. The primary end point was progression to chronic kidney disease (CKD) stage 3 (estimated glomerular filtration rate [eGFR] < 60 ml/min per 1.73 m²). Secondary end points were the development of hypomagnesemia or extrarenal disorders, including hyperuricemia and hyperglycemia.

Results: Progression toward CKD stage 3 was significantly delayed in patients with the 17q12del compared to patients with *HNF1B* variants (hazard ratio [HR]: 0.29, 95% confidence interval [CI]: 0.19–0.44, $P < 0.001$). Progression toward CKD stage 3 was also significantly delayed when *HNF1B* variants involved the *HNF1B* Pit-1, Oct-1, and Unc-86 homeodomain (POU_H) DNA-binding and transactivation domains rather than the POU-specific domain (POU_S) DNA-binding domain (HR: 0.15 [95% CI: 0.06–0.37], $P < 0.001$ and HR: 0.25 [95% CI: 0.11–0.57], $P = 0.001$, respectively). Finally, the 17q12del was positively associated with hypomagnesemia and negatively associated with hyperuricemia, but not with hyperglycemia.

Conclusion: Patients with the 17q12del display a significantly better kidney survival than patients with other *HNF1B* variants; and for the latter, variants in the POU_S DNA-binding domain lead to the poorest kidney survival. These are clinically relevant *HNF1B* kidney genotype-phenotype correlations that inform genetic counseling.

Kidney Int Rep (2024) 9, 2514–2526; <https://doi.org/10.1016/j.ekir.2024.05.007>

KEYWORDS: chronic kidney disease; genotype-phenotype correlation; *HNF1B* disease; outcome

© 2024 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

H*NF1B*-related disease is identified in 20% to 30% of fetuses with renal abnormalities. *HNF1B* disease, initially described as the renal cysts and diabetes syndrome (OMIM # 137920), has evolved to a much wider phenotype. Indeed, variants or whole gene deletions of *HNF1B* are the most common prenatal cause of hyperechogenic kidneys with or without cysts.¹ When detected in the postnatal period, *HNF1B* disease is the most common cause of isolated renal hypodysplasia.^{2,3} Other renal manifestations associated with *HNF1B* disease include multicystic dysplastic kidneys,

glomerulocystic kidney disease, oligomeganephronia, renal agenesis, renal hypoplasia, urinary tract defects, familial juvenile hyperuricemic nephropathy, and renal interstitial fibrosis.^{4–6} This wide variety of kidney phenotypes is probably due to the fact that the *HNF1B* protein is involved in the majority of the stages of kidney development, from the outgrowth of the uretic bud and its early branching⁷ to the elongation of the renal tubules,⁸ and is still expressed in the mature kidney. Individuals with *HNF1B* disease may also suffer from electrolyte disturbances such as

hypomagnesemia and hyperuricemia, pancreatic hypoplasia, early-onset diabetes mellitus, as well as liver and genital defects.⁹

HNF1B is a transcription factor that controls key cystic disease genes during kidney development,¹⁰ where it controls the expression of genes required for kidney metabolism and solute transport by tubular epithelial cells in the adult kidney.^{11,12} *HNF1B* contains a dimerization domain located at the N-terminus of the protein which mediates the formation of *HNF1B* homodimers or heterodimers with the related protein *HNF-1 α* .¹³ The protein also contains a homeo DNA-binding domain, consisting of a Pit-1, Oct-1, and Unc-86 (POU) homeodomain (POU_h) and POU-specific domain (POU_s). POU_h is a classic homeodomain which recognizes DNA, whereas POU_s cooperates with POU_h to enhance the affinity and specificity of DNA binding.¹⁴ Finally, the C-terminal region of *HNF1B* contains a transactivation domain that is responsible for coactivator recruitment and transcriptional regulation.¹⁵

HNF1B disease transmission follows a dominant pattern, however, *de novo* variants are very common. Genetic alterations in *HNF1B* disease can be broadly divided into two categories.⁹ One category comprises base substitutions and small insertions and/or duplications and/or deletions, leading to missense, nonsense, frameshift, and splicing variants, most of which are described to be located in the DNA-binding and N-terminal dimerization domain of the protein.⁹ These *HNF1B* variants account for approximately 41% to 44% of patients with *HNF1B* disease.⁹ The other category is represented by the so-called 17q12del, which spans a region of approximately 1.5 Mb in which are located 14 genes, including *HNF1B*.⁹

The 17q12del compared to the *HNF1B* variants,^{16–19} has already been shown to be associated with an increased risk of neurodevelopmental disorders in the pediatric population. Furthermore, in adults, the 17q12del has been suggested to be associated with improved kidney function, as demonstrated in a small subset of 169 adult patients.²⁰ However, no clear kidney genotype-phenotype correlation has been established; though nowadays, *HNF1B* genetic testing is routinely obtained in most clinics for patients with developmental kidney abnormalities. Improved insight into this relationship would further inform the management and counseling of patients with *HNF1B* disease. We therefore aimed to investigate the association of *HNF1B* variants and the 17q12del with the development of CKD in a large multicenter European cohort of 521 individuals with genetically well-characterized *HNF1B* disease.

METHODS

Patients and Data Collection

Observational anonymized data on patients with *HNF1B* disease were retrospectively collected from different European registries under the European Reference Network for rare kidney diseases (www.erknet.org) umbrella. Minimal data necessary for the study included the following: (i) the pathogenic *HNF1B* variant, specifically whether it was either the 17q12del or single nucleotide variants (missense, nonsense), small deletions or duplications (*HNF1B* variants were identified for 27% with Sanger sequencing, for 23% with multiplex ligation-dependent probe amplification, for 9% with quantitative multiplex polymerase chain reaction of short fluorescent fragments, for 8% with comparative genomic hybridization array and for 3% with fluorescence in situ hybridization); (ii) information on the inheritance of *HNF1B* genotype (the *de novo* status was determined by targeted analysis in parents, by trio-based exome sequencing and by consulting family history or sonography of parents in 78%, 19%, and 3% of the cases, respectively); (iii) the prenatal or postnatal sonomorphologic kidney phenotype at diagnosis (multicystic dysplastic kidneys, cortical cystic kidneys, hyperechogenic kidneys, hypoplastic kidneys, agenesis, and “other”) and whether structural anomalies were unilateral or bilateral. Development of hypomagnesemia, hyperuricemia, and hyperglycemia was recorded. Maximum follow-up of patients was requested, preferably with new ultrasound (every 2–3 years) and biochemical-data (every 1–2 years, blood magnesium, potassium, uric acid, serum creatinine with associated method used [Jaffe or enzymatic]). We did not collect information on whether all patients were index patients or kindreds of index patients. Nonpaternity was not ruled out. Data were retrospectively collected from 53 centers in 14 European countries according to local standard-of-care. Given that *HNF1B* related disease is congenital, we considered the start of patient follow-up being birth.

Clinical Parameters

The CKD-Epidemiology Collaboration equation²¹ for eGFR calculation was used for patients aged ≥ 15 years. For patients aged < 15 years, the eGFR was calculated using the Schwartz formula.²² In the particular case of eGFR estimation in the neonatal period (≤ 1 month), the Schwartz coefficient used was 0.31 and $\text{eGFR} = 0.31 \times (\text{height/serum creatinine})$.²³ CKD stage 3 was defined by an $\text{eGFR} < 60 \text{ ml/min per } 1.73 \text{ m}^2$ for patients aged ≥ 15 years. For patients aged 2 to 15 years, CKD stage 3 was defined by an $\text{eGFR} < 60 \text{ ml/min per } 1.73 \text{ m}^2$ in at least 2

consecutive visits. The thresholds for the definitions of hypomagnesemia, hyperuricemia, or hyperglycemia were <0.6 mmol/l, >320 μ mol/l or >1.26 g/l (fasting), respectively, on at least 1 measurement.

Ethics

The data were fully anonymized. Approval was obtained from the medical ethical committees or institutional review boards for all participating countries and written informed consent was obtained from all participants or parents in adherence to the declaration of Helsinki.

Statistical Analysis

Patient characteristics were reported as number (percentage) or median (25%–75%) for qualitative and quantitative variables, respectively. They were compared according to the *HNF1B* genotype using a Chi-square test ($N > 5$) or a Fisher test ($N \leq 5$) for categorical variables and a Wilcoxon rank sum test for continuous variables ((gtsummary package in R statistical software, V4.0.1)).

In the specific case of kidney ultrasound characteristics, where a global significant effect ($P < 0.05$) of the *HNF1B* genotype was observed, additional analysis was performed according to an approach based on calculating adjusted standardized residuals,²⁴ in order to identify features making the greatest contribution to the Chi-square test result: adjusted standardized residual ≥ 3 or ≤ -3 indicated that there were more or less patients, respectively, with the considered feature than would be expected by chance. Univariate and multivariate Cox proportional HR models were built to estimate the impact of *HNF1B* genotype on CKD stage 3 development (proportional hazard assumption was verified for each model using Schoenfeld residuals method) (survdiff package in R, V4.0.1). Progression to CKD was not evaluated in children aged <2 years, due to changes in eGFR in early life. HRs are reported with 95% CIs and P -value to assess whether the HR is statistically significantly different from 1 (survival package of R, V4.0.1). The equality of survival distributions was compared using log-rank test (survdiff package of R, V4.0.1). Considering that *HNF1B* disease is a congenital disease, the start of the follow-up was birth. Survival curves only used data from children aged ≥ 2 years. Odd ratios for hypomagnesemia, hyperuricemia, and hyperglycemia were obtained using logistic regression and reported with 95% CIs and P -value to assess whether the odd ratios is statistically significantly different from 1 (stats package of R, V4.0.1).

For analysis of eGFR evolution after birth, the first week was excluded, considering that creatinine levels reflected that of the mother. Changes in eGFR were

assessed using a generalized linear mixed model with a negative binomial distribution, considering the *HNF1B* genotype (17q12del or *HNF1B* variant) as random effect (lme4 package in R, V4.0.1). For each period analyzed (1 week–2 years and 2–18 years) 4 models were analyzed as follows: (i) 1 model without random effect, (ii) a mixed-effect model with a random effect for the intercept and a fixed slope, (iii) a mixed-effect model with a random effect for the slope and a fixed intercept, and (iv) a mixed-effect model with both a random intercept and a random slope. These 4 models were compared among each other using Akaike's information criterion corrected for small samples.²⁵ The model with the lowest Akaike's information criterion and with a value of at least 2 Akaike's information criterion units from the other models was considered the model best fitting the data. Patients with <3 eGFR measurements during the period of interest were excluded from the generalized linear mixed model analysis.

RESULTS

Cohort Description

Retrospective data were initially collected from registries via ERKNet for 536 patients with suspected *HNF1B* disease from 53 centers in 14 European countries (Supplementary Figure S1). Fifteen patients were excluded because no clear information on the *HNF1B* variant was obtained leading to 340 patients with the 17q12del and 181 patients with *HNF1B* variants (Figure 1). Next, 13 additional patients were excluded in the *HNF1B* variants group because they were described as benign *HNF1B* variants (p.Val61Gly, p.Gly76Cys, p.Asp82Asn, p.Asn228Lys and p.His336Asp, Figure 1 and Supplementary Table S1 [lower grey section]). This led to a total of 168 patients with *HNF1B* variants (Supplementary Table S1). These *HNF1B* variants were mainly found in the DNA-binding domains POU_s and POU_h (67%, 88/132) and, to a lesser extent, in the transactivating domain (19%, 25/132) (Figure 2). The majority of the *HNF1B* variants were nucleotide substitutions (74%, Supplementary Figure S2a) leading to 47% of missense and 20% of nonsense variants at the protein level (Supplementary Figure S2b).

Patients had a predominant antenatal diagnosis (58%, Table 1), a median of 6 visits and 11 years of follow-up with no difference between the 17q12del and the *HNF1B* variants (Supplementary Table S2). A 17q12del was identified in 67% (340/508) of the patients and occurred *de novo* in 53% of the cases (Table 1); 74% of the *HNF1B* variants were inherited.

At diagnosis, main kidney malformations observed with ultrasound were cortical cystic disease or hyper-echogenic kidneys, which together affected $>80\%$ of




Figure 1. Overview of patient recruitment and patient exclusion. *Definition of pathogenicity or variant of unknown significance (VUS) was based on the merger of the 3 following databases. ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar> (db accessed July 11, 2023); LOVD (https://databases.lovd.nl/shared/variants/HNF1B#object_id=VariantOnTranscript%2CVariantOnGenome&id=HNF1B&order=VariantOnTranscript%2FDNA%2CASC&search_transcriptid=00009498&search_VariantOnTranscript/DNA=c.738G%3ET&page_size=100&page=1 (db accessed July 11, 2023)) and Leipzig_University (<https://www.hnf1b.org> (db accessed July 11, 2023)).²⁶ A variant was marked as pathogenic if in at least 1 database the variant was labelled “pathogenic”. In all other cases a variant was labelled “VUS.”

the patients (Figure 3). A single functional kidney due to unilateral multicystic dysplastic kidney or agenesis was observed in 18% of the patients (Table 1). The risk

of having hypoplasia was significantly lower in patients with the 17q12del than in patients with *HNF1B* variants (1.2% vs. 5.5%, Figure 3).




Figure 2. Position of molecular modifications on the *HNF1B* gene and HNF1B protein in 508 patients with *HNF1B* disease. Domains in the HNF1B protein were positioned according to.²⁷

Table 1. Patients characteristics at inclusion

Patient characteristics	n	HNF1B		P-value ^a	Q-value ^b
		HNF1B variants	17q12del		
All	508	168	340		
Sex	507			0.503	0.575
Female	208 (41%) ^c	72 (43%)	136 (40%)		
Male	299 (59%)	95 (57%)	204 (60%)		
Origin	286			<0.001	<0.001
De novo	123 (43%)	28 (26%)	95 (53%)		
Inherited	163 (57%)	80 (74%)	83 (47%)		
Transmission mode (in case of inherited variants)	156			0.036	0.097
Mother	100 (64%)	44 (55%)	56 (73%)		
Father	55 (35%)	34 (43%)	21 (27%)		
Mother + father	1 (0.6%)	1 (1.3%)	0 (0%)		
Diagnosis	309			0.023	0.090
Antenatal	180 (58%)	49 (49%)	131 (63%)		
Postnatal	129 (42%)	51 (51%)	78 (37%)		
Age at antenatal diagnosis (wa)	70	24 (20–30) ^d	24 (20–27)	0.311	0.575
Age at postnatal diagnosis (y)	109	3 (0–17)	4 (1–17)	0.454	0.575
Number of kidneys with US lesions	474			0.405	0.575
No	3 (0.6%)	2 (1.3%)	1 (0.3%)		
1	48 (10%)	16 (10%)	32 (10.0%)		
2	423 (89%)	135 (88%)	288 (90%)		
Number of functional kidneys	479			0.895	0.895
2	391 (82%)	126 (81%)	265 (82%)		
1	88 (18%)	29 (19%)	59 (18%)		

^aPearson's Chi-square test; Fisher exact test; Wilcoxon rank sum test.^bFalse discovery rate correction for multiple testing.^cn (%)^dMedian (25%–75%).

Progression to Chronic Kidney Failure

Twenty-one percent of the patients progressed toward the primary kidney end point (CKD stage 3, eGFR < 60 ml/min per 1.73 m²) during follow-up. This was less frequent in the population with the 17q12del than with

HNF1B variants (12% vs. 39%, $P < 0.001$, [Supplementary Table S2](#)). In addition, progression toward CKD-stage 3 was significantly delayed in patients with the 17q12del compared to patients with HNF1B variants ([Figure 4](#), HR: 0.29 [95% CI: 0.19–0.44], $P <$




Figure 3. Kidney ultrasound characteristics at diagnosis in the 521 patients with HNF1B variants. A global significant effect ($P = 0.005$) of the HNF1B genotype was observed. The adjusted standardized residual was equal to 4.80 for hypoplasia in patients with HNF1B variants, thereby indicating (≥ 3 , see statistical analysis) that there were more patients with hypoplasia than would be expected by chance. In contrast, the adjusted standardized residual was equal to -6.99 for hypoplasia in patients with the 17q12del, thereby indicating (≤ -3 , see statistical analysis) that there were less patients with hypoplasia than would be expected by chance. This strongly suggests that the risk of having hypoplasia was significantly lower in patients with the 17q12del than in patients with HNF1B variants (*).




Figure 4. Progression to CKD stage 3 of patients the 17q12del compared to *HNF1B* variants. Progression to CKD is significantly delayed in patients with the 17q12del compared to patients with *HNF1B* variants (HR: 0.29 [95% CI: 0.19–0.44], $P < 0.001$). The survival curve was generated using data from children aged ≥ 2 years to dismiss changes in eGFR in early life. The point in time of progression to CKD stage 3 (eGFR < 60 ml/min per 1.73 m^2) was entered as the chronological age of each patient. We considered that patients entered the study (baseline) at birth given the fact the *HNF1B* disease is a congenital nephropathy. The log-rank test for difference in survival yielded a P -value < 0.0001 , indicating that the patients with 17q12del and *HNF1B* variants differed significantly in progression toward CKD stage 3. CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio.

0.001) with CKD-free survival of 87% (95% CI: 81–93) for the 17q12del versus 63% (95% CI: 54–73) for *HNF1B* variants at the age of 18 years. The association of *HNF1B* genotype with progression toward CKD stage 3 was still observed after adjustment for known CKD risk factors, including sex or hyperglycemia (HR: 0.30 [95% CI: 0.19–0.45], $P < 0.001$).

Patients with the 17q12del also developed end-stage kidney failure (ESKF) less frequently (Supplementary Table S2, $P < 0.001$) and displayed a delayed progression to ESKF (Supplementary Figure S3a, $P < 0.001$) with ESKF-free survival of 97% (95% CI: 95–100) for the 17q12del versus 86% (95% CI: 79–94) for *HNF1B* variants at the age of 18 years. Even after

reaching CKD stage 3, a tendency for a slower progression to ESKF for the 17q12del was observed (Supplementary Figure S3b, $P = 0.14$).

Individuals with the 17q12del had higher eGFR early in life (68 ml/min per 1.73 m^2 [95% CI: 60–76] vs. 46 ml/min per 1.73 m^2 [95% CI: 39–55] at 1 week, as defined by generalized linear mixed model analysis, Figure 5a). These higher eGFR values persisted throughout childhood (1 week–2 years, Figure 5a) and adolescence (2–18 years, Figure 5b). However, no difference between the 2 groups with respect to evolution of eGFR could be demonstrated (Figure 5a and b).

In case of the 17q12del, patients with a single functional kidney (due to 1 multicystic dysplastic




Figure 5. Impact of the *HNF1B* genotype on eGFR trajectories in the pediatric period. Comparison of eGFR trajectories between the *HNF1B* variants and the 17q12del (a) before 2 years (10 and 21 patients for *HNF1B* variants and the 17q12del, respectively) and (b) between 2 and 18 years (91 and 175 patients for *HNF1B* variants and the 17q12del, respectively). Patients with <3 eGFR measurements during the period of interest were excluded. Individual and mean (bold) trajectories are plotted. The arrows and values indicate the mean (95% CI) eGFR at 1 week after birth. CI, confidence interval; eGFR, estimated glomerular filtration rate.

kidney or unilateral agenesis) displayed accelerated CKD progression compared to patients with 2 functional kidneys (Supplementary Figure S4a, HR: 2.32 [95% CI: 1.04–5.17], $P = 0.04$). In contrast, in the group with *HNF1B* variants, the number of functional kidneys was not associated with CKD progression (HR: 0.92 [95% CI: 0.43–1.98], $P = 0.836$, Supplementary Figure S4b).

As observed in other studies,⁹ the majority of the patients had *HNF1B* variants located in the POU domains followed by variants in the transactivation domain. Patients with variants located in the POU_h or transactivation domains progressed slower toward CKD stage 3 than patients with variants in the POU_s domain (Figure 6, HR: 0.15 [95% CI: 0.06–0.37], $P < 0.001$ and HR: 0.25 [95% CI: 0.11–0.57], $P = 0.001$, respectively). Adjustment by sex or hyperglycemia did not impact progression (HR: 0.14 [95% CI: 0.05–0.35], $P < 0.001$ and HR 0.22 [95% CI: 0.08–0.58], $P = 0.002$, respectively).

In contrast, the type of variants (missense, nonsense, splicing or frameshift) were not specifically associated with kidney survival (Supplementary Figure S5).

Hypomagnesemia or Extrarenal Disorders

We next investigated whether there was a difference between the 17q12del and *HNF1B* variants in the development of hypomagnesemia or extrarenal disorders. Hypomagnesemia (defined as plasma magnesium <0.6 mmol/l) was observed in 29% of the patients during follow-up (Supplementary Table S2)

and was significantly more frequent in patients with the 17q12del (HR: 2.12 [95% CI: 1.32–3.50], $P = 0.002$, Figure 7a). However, onset of hypomagnesemia was independent of the affected (POU or transactivation) protein domains (Figure 7d).

Overall, 65% of the patients developed hyperuricemia (defined by plasma uric acid >320 μ mol/l, Supplementary Table S2) and was significantly less frequent in patients with the 17q12del compared to the *HNF1B* variants (HR: 0.57 [95% CI: 0.36–0.87], $P = 0.011$, Figure 7b). Among the *HNF1B* variants, patients with variants in the POU_h domain, but not those with variants in the transactivation domain, developed significantly less frequent hyperuricemia than patients with variants in the POU_s (HR: 0.30 [95% CI: 0.11–0.79], $P = 0.018$, Figure 7e). Finally, only 12% of the patients developed hyperglycemia (blood glucose > 1.26 g/l, Supplementary Table S2), which did not correlate with a specific *HNF1B* genotype even though a tendency to be less frequent in the population with the 17q12del was observed (HR: 0.60 [95% CI: 0.35–1.05], $P = 0.069$, Figure 7c). No significant difference for the development of hyperglycemia was observed between variants in the POU or transactivation domains (Figure 7f).

DISCUSSION

Genotype-kidney survival phenotype correlations in patients with *HNF1B* disease have long been sought to improve genetic counseling. For a long time, there was




Figure 6. Impact of variants in the different *HNF1B* domains on the progression to CKD stage 3. Variants located in the POU_h and transactivation domains displayed a significantly delayed progression toward CKD stage 3 compared to patients with variants in the POU_s domain (HR: 0.15 [95% CI: 0.06–0.37], $P < 0.001$ and HR: 0.25 [95% CI: 0.11–0.57], $P = 0.001$, respectively). The survival curve was generated using data from children aged ≥ 2 years to dismiss changes in eGFR in early life. The point in time of progression to CKD stage 3 (eGFR < 60 ml/min per 1.73 m²) was entered as the chronological age of each patient. We considered that patients entered the study (baseline) at birth given that *HNF1B* disease is a congenital nephropathy. CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; Trans, transactivation domain. The log rank test for difference in survival yielded a P -value < 0.0001 , indicating that the patients with variants in the 3 *HNF1B* domains differed significantly in progression toward CKD stage 3.

no demonstrated correlation between genotype and kidney phenotype in *HNF1B* disease.⁹ However, a first small scale study in 2010, including 70 pediatric patients, showed a lower proportion of patients with renal failure in individuals with the 17q12del than in individuals with nonsense, splice, or frameshift *HNF1B* variants.⁴ Subsequently, a study in 2016 with 38 pediatric and adult individuals with *HNF1B* disease showed that patients with the 17q12del displayed higher eGFR compared to patients with *HNF1B* variants.¹⁸ Finally in 2018, Dubois-Lafforgue *et al.*²⁰ showed in a larger population of 169 adult patients

with *HNF1B* disease, primarily selected for *HNF1B* disease screening due the presence of maturity-onset diabetes of the young, that individuals with the 17q12del less often had CKD3–4/ESKF at diagnosis and at long-term follow-up (12–14.5 years). This present report clearly confirms in a large cohort of 521 patients with *HNF1B* disease that the 17q12del is associated with significantly better kidney survival than the *HNF1B* variants across all ages, including pediatric and adult patients. Moreover, this study identified for the first time that variants located in the POU_s DNA binding domain of *HNF1B* had a significantly worse




Figure 7. The 17q12del and *HNF1B* variants in hypomagnesemia or extrarenal disorders. (a) Hypomagnesemia (magnesium < 0.6 mmol/l) was more frequent in patients with the 17q12del compared to patients with *HNF1B* variants. (b) Hyperuricemia (uric acid > 320 μ mol/l) was less frequent in patients with the 17q12del compared to patients with *HNF1B* variants. (c) Hyperglycemia (fasting blood glucose > 1.26 g/l) was not different in the patient groups. (d) Hypomagnesemia was not different between patients with variants in the POU_s, POU_h, and transactivation domains. (e) Hyperuricemia was less frequent in patients with variants in the POU_h than in the POU_s and transactivation domains. (f) Hyperglycemia was not different between patients with variants in the POU_s, POU_h, and transactivation domains.

kidney survival than variants located in the POU_h or transactivation domains.

The identification in childhood of a 17q12del and the presence of 2 functional kidneys will allow to reassure the parents with the information that their child has a low probability of developing CKD stage 3 before the age of 18 years. In contrast, it has been clearly documented that the 17q12del is associated with an increased risk of developing neurodevelopmental disorders.^{16–19} Therefore, this important aspect should be considered and included in parental counseling. The presence of an *HNF1B* variant instead of the 17q12del would be an argument for early-in-life monitoring of signs of kidney failure and adopt conservative management. In addition, if the other *HNF1B* variant is located in the POU_s DNA binding domain of the HNF1B protein, this monitoring should be further reinforced because variants in this domain compared to the POU_h and transactivation domains led to a particularly high risk of progression to CKD stage 3 in our study.

The difference in terms of renal function between patients with the 17q12del and those with the *HNF1B* variants appears to be already present in the neonatal period, however, without differentially impacting eGFR evolution at least up to 18 years of age.

On a molecular level, the fact that the 17q12del resulted in a less severe kidney phenotype compared to the *HNF1B* variants is surprising. Such a difference has also been observed in mice. *Hnfb*^{+/-} mice were phenotypically normal²⁸ with increased rather than decreased²⁹ kidney HNF1B protein abundance, whereas mice carrying a heterozygous *HNF1B* splice variant lead presence of bilateral cystic kidneys with low kidney HNF1B protein levels.²⁹ A possible explanation may be the fact that missense *HNF1B* variants might lead to a dominant negative effect because the variants are for the greater part located in the DNA-binding and N-terminal dimerization domain of the HNF1B protein⁹ and analysis of a Leu168Pro *HNF1B* variant located in the POU_s domain clearly demonstrated a dominant effect on HNF1B activity when coexpressing the wild type and Leu168Pro *HNF1B* variant *in vitro*.³⁰

The observation that variants in the POU_s domain led to a more severe kidney outcome than variations in the POU_h and transactivation domains is intriguing. It is thought that on the molecular level, the POU_s domain cooperates with POU_h to enhance the binding affinity and specificity of DNA binding and is not the initial DNA binding site.¹⁴ However, *in vitro*, missense variants in the POU_s domain lead in general to a more

pronounced reduction in *HNF1B* protein stability, transcriptional activity, and DNA binding than missense variants in the POU_h domain.¹⁴

Hypomagnesemia developed in 29% of the patients with *HNF1B* disease. Hypomagnesemia is a common feature due to renal magnesium wasting in patients with *HNF1B* disease.⁹ However, we report for the first time a higher risk for this disorder in patients with the 17q12del. In contrast the risk of hyperuricemia, observed 65% of the patients during follow-up, was lower in patients with the 17q12del and in patients with a variant in the POU_h compared to the POU_s and transactivation domains.

The main strength of this study is the large number (>500) of patients enrolled for a rare disease. Patients were enrolled in a variety of >50 clinics, representing a diversity of health care systems across 14 European countries. In addition, the frequency of the 17q12del in our large cohort is close to what has been reported in the literature, 67% in the current study versus 56% to 59% in the literature.⁹ Therefore, the patient population studied is similar to routine clinical care.

Limitations of this study were the fact that this is a relatively young cohort with few patients aged over 20 years (59/521) at the end of the follow-up. This probably explains the low percentage (12%) of patients who developed hyperglycemia during follow-up in our cohort. It would therefore be interesting to reanalyze this cohort with an additional decade of follow-up. We also did not study the aforementioned development of psychiatric and autism spectrum disorders in our cohort¹⁶⁻¹⁹ due to the trade-off of focusing on the kidney to maximize the number of patients included. Only 2 variants were located in the dimerization domain. Finally, this was a retrospective study.

In conclusion, our study has identified clinically relevant genotype-phenotype correlations in patients with *HNF1B* disease predicting kidney survival that inform genetic counseling.

APPENDIX

List of Additional Collaborators of the *HNF1B* Variant Study Group

Gema Ariceta, MD, PhD (Pediatric Nephrology, University Hospital Vall d'Hebron, Barcelona, Spain); Elisa Benetti, MD, PhD (Pediatric Nephrology, Dialysis and Transplant Unit, Department of Women's and Children's Health, Padua University Hospital, Padua, Italy); Marcus R Benz, MD (Pediatric Nephrology Dachau, Dachau, Germany); Anna Bjerre, MD, PhD (Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway); Bernard R Boudailliez, MD (Service de Néphrologie

Pédiatrique, Département de Pédiatrie, CHU Amiens, Amiens, France); Antonia Bouts, MD, PhD (Emma Children's Hospital, Amsterdam University Medical Centers, Department of Pediatric Nephrology, Amsterdam Reproduction & Development, Amsterdam, the Netherlands); Jens Drube, (Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School Children's Hospital, Hannover, Germany); Ann Christin Gjerstad, MD, PhD (Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway); Augustina Jankauskiene, MD, PhD (Pediatric Center, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania); Eszter Jávorszky, PhD (MTA -SE Lendület Nephrogenetic Laboratory, Budapest, Hungary); Nadine Jay, MD (Service de Pédiatrie, CHU de Brest, Brest, France); Martin Kirschstein, MD, PhD (Department of Pediatrics, General Hospital, Celle, Germany); Nataša Marčun Varda, MD, PhD (University Medical Centre Maribor, Department of Paediatrics, Maribor, Slovenia); Olivier Niel, MD, PhD (Pediatric Nephrology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg); François Nobili, MD (Service de Pédiatrie 2, CHU Besancon, Besancon, France); Christine Pietrement, MD, PhD (Unité de Néphrologie Pédiatrique CHU Reims, Reims, France); Dovile Ruzgiene, MD (Pediatric Center, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania); Raphael Schild, MD (University Children's Hospital, University Medical Center Hamburg Eppendorf, Hamburg, Germany); Hagen Staude, MD (Department of Pediatric Nephrology, University Children's Hospital, Rostock, Germany); Kálmán Tory, MD, PhD (MTA -SE Lendület Nephrogenetic Laboratory, Budapest, Hungary); Michel Tsimaratos, MD, PhD (Pédiatrie Multidisciplinaire Timone, Aix -Marseille Université, Marseille, France); Ulrike Walden, MD (Paediatric and Adolescent Medicine, University Medical Center, Augsburg, Germany); and Hildegard Zappel, MD (University Children's Hospital Göttingen, Göttingen, Germany).

DISCLOSURE

All the authors declared no competing interests.

ACKNOWLEDGMENTS

NEOCYST is funded by the German Federal Ministry of Education and Research—grant code 01GM1515A. This project has been supported by the European Reference Network for rare kidney diseases (ERKNet). ERKNet is funded by the European Union within the framework of the EU4Health Programme (grant No.HS g-23-49).

DATA AVAILABILITY STATEMENT

All raw patient inclusion and follow-up data used in the study of the can be found in [Supplementary Table S3](#).

SUPPLEMENTARY MATERIAL

Supplementary File (PDF and Excel)

Figure S1. An international multicenter study. (a) 14 European countries participated in the study. A total of (b) 22 centers from France and (c) 14 centers from Germany, the 2 major participating countries, were involved.

Figure S2. Distribution of *HNF1B* variants other than the 17q12del. (a) Nature of variants and (b) resulting variants.

Figure S3. Progression to ESKF of patients with *HNF1B* disease. (a) Progression to ESKF is significantly delayed in patients with the 17q12del compared to patients with *HNF1B* variants. (b) Progression to ESKF after developing CKD is not different between the 62 patients with *HNF1B* variants and 33 patients with the 17q12del. The survival curves were generated using data from children aged ≥ 2 years to dismiss changes in eGFR evolution in early life. The point in time of progression to ESKF was entered as the chronological age of each patient. We considered that patients entered the study (baseline) at birth given that *HNF1B* disease is a congenital nephropathy. In (a), the log-rank test for difference in survival yielded a *P*-value < 0.0001 , indicating that the patients with 17q12del and *HNF1B* variants differed significantly in progression toward ESKF. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESKF, end-stage kidney failure.

Figure S4. Impact of 1 or 2 functional kidneys in patients with *HNF1B* disease on progression to CKD stage 3. (a) Kidney survival of patients with the 17q12del is worse in patients with 1 functional kidney. (b) Kidney survival of patients with *HNF1B* variants is similar irrespective of the number of functional kidneys. The survival curves were generated using data from children aged ≥ 2 years to dismiss changes in eGFR in early life. The point in time of progression to CKD stage 3 (eGFR < 60 ml/min per 1.73 m^2) was entered as the chronological age of each patient. We considered that patients entered the study (baseline) at birth given that *HNF1B* disease is a congenital nephropathy. In (a) The log-rank test for difference in survival yielded a *P*-value of 0.034, indicating that the patients with 17q12del with 1 functional kidney differed significantly in progression toward CKD stage 3. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.

Figure S5. Impact of the nature of the change at the *HNF1B* protein level on progression to CKD stage 3. Kidney survival of patients is not different between missense, nonsense, splicing, or frameshift *HNF1B* variants. The survival curves were generated using data from children aged > 2 years to dismiss changes in eGFR in early life. The point in time of progression to CKD stage 3 (eGFR < 60 ml/min per 1.73 m^2) was entered as the chronological age of each patient. We considered that patients entered

the study (baseline) at birth given that *HNF1B* disease is a congenital nephropathy. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.

Table S1. Characteristics of *HNF1B* gene variants.

Table S2. Follow-up data of patients with *HNF1B* disease.

Table S3. Individual patient data. (Excel)

STROBE Statement.

REFERENCES

- Decramer S, Parant O, Beaufils S, et al. Anomalies of the TCF2 gene are the main cause of fetal bilateral hyperechogenic kidneys. *J Am Soc Nephrol.* 2007;18:923–933. <https://doi.org/10.1681/ASN.2006091057>
- Weber S, Moriniere V, Knuppel T, et al. Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the Escape study. *J Am Soc Nephrol.* 2006;17:2864–2870. <https://doi.org/10.1681/ASN.2006030277>
- Thomas R, Sanna-Cherchi S, Warady BA, Furth SL, Kaskel FJ, Gharavi AG. *HNF1B* and *PAX2* mutations are a common cause of renal hypodysplasia in the CKiD cohort. *Pediatr Nephrol.* 2011;26:897–903. <https://doi.org/10.1007/s00467-011-1826-9>
- Heidet L, Decramer S, Pawtowski A, et al. Spectrum of *HNF1B* mutations in a large cohort of patients who harbor renal diseases. *Clin J Am Soc Nephrol.* 2010;5:1079–1090. <https://doi.org/10.2215/CJN.06810909>
- Bellanné-Chantelot C, Chauveau D, Gautier JF, et al. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. *Ann Intern Med.* 2004;140:510–517. <https://doi.org/10.7326/0003-4819-140-7-200404060-00009>
- Edghill EL, Bingham C, Ellard S, Hattersley AT. Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. *J Med Genet.* 2006;43:84–90. <https://doi.org/10.1136/jmg.2005.032854>
- Lokmane L, Heliot C, Garcia-Villalba P, Fabre M, Cereghini S. *vHNF1* functions in distinct regulatory circuits to control ureteric bud branching and early nephrogenesis. *Development.* 2010;137:347–357. <https://doi.org/10.1242/dev.042226>
- Gresh L, Fischer E, Reimann A, et al. A transcriptional network in polycystic kidney disease. *EMBO J.* 2004;23:1657–1668. <https://doi.org/10.1038/sj.emboj.7600160>
- Clissold RL, Hamilton AJ, Hattersley AT, Ellard S, Bingham C. *HNF1B*-associated renal and extra-renal disease—an expanding clinical spectrum. *Nat Rev Nephrol.* 2015;11:102–112. <https://doi.org/10.1038/nrneph.2014.232>
- Coffinier C, Thépot D, Babinet C, Yaniv M, Barra J. Essential role for the homeoprotein *vHNF1/HNF1beta* in visceral endoderm differentiation. *Development.* 1999;126:4785–4794. <https://doi.org/10.1242/dev.126.21.4785>
- Ferrè S, Igarashi P. New insights into the role of *HNF-1β* in kidney (patho)physiology. *Pediatr Nephrol.* 2019;34:1325–1335. <https://doi.org/10.1007/s00467-018-3990-7>
- Faguer S, Decramer S, Chassaing N, et al. Diagnosis, management, and prognosis of *HNF1B* nephropathy in adulthood. *Kidney Int.* 2011;80:768–776. <https://doi.org/10.1038/ki.2011.225>
- Mendel DB, Khavari PA, Conley PB, et al. Characterization of a cofactor that regulates dimerization of a mammalian homeodomain protein. *Science.* 1991;254:1762–1767. <https://doi.org/10.1126/science.1763325>

14. Lu P, Rha GB, Chi YI. Structural basis of disease-causing mutations in hepatocyte nuclear factor 1beta. *Biochemistry*. 2007;46:12071–12080. <https://doi.org/10.1021/bi7010527>
15. Barbacci E, Chalkiadaki A, Masdeu C, et al. HNF1beta/TCF2 mutations impair transactivation potential through altered co-regulator recruitment. *Hum Mol Genet*. 2004;13:3139–3149. <https://doi.org/10.1093/hmg/ddh338>
16. Laliève F, Decramer S, Heidet L, et al. School Level of children carrying a HNF1B variant or a deletion. *Eur J Hum Genet*. 2020;28:56–63. <https://doi.org/10.1038/s41431-019-0490-6>
17. Moreno-De-Luca D, SGENE Consortium, Mulle JG, et al. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. *Am J Hum Genet*. 2010;87:618–630. <https://doi.org/10.1016/j.ajhg.2010.10.004>
18. Clissold RL, Shaw-Smith C, Turnpenny P, et al. Chromosome 17q12 microdeletions but not intragenic HNF1B mutations link developmental kidney disease and psychiatric disorder. *Kidney Int*. 2016;90:203–211. <https://doi.org/10.1016/j.kint.2016.03.027>
19. Dubois-Laforgue D, Bellanné-Chantelot C, Charles P, et al. Intellectual disability in patients with MODY due to hepatocyte nuclear factor 1B (HNF1B) molecular defects. *Diabetes Metab*. 2017;43:89–92. <https://doi.org/10.1016/j.diabet.2016.10.003>
20. Dubois-Laforgue D, Cornu E, Saint-Martin C, et al. Diabetes, associated clinical spectrum, long-term prognosis, and genotype/phenotype correlations in 201 adult patients with hepatocyte nuclear factor 1B (HNF1B) molecular defects. *Diabetes Care*. 2017;40:1436–1443. <https://doi.org/10.2337/dc16-2462>
21. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150:604–612. <https://doi.org/10.7326/0003-4819-150-9-200905050-00006>
22. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. *J Am Soc Nephrol*. 2009;20:629–637. <https://doi.org/10.1681/ASN.2008030287>
23. Smeets NJL, Int'Hout J, van der Burgh MJP, Schwartz GJ, Schreuder MF, de Wildt SN. Maturation of GFR in term-born neonates: an individual participant data meta-analysis. *J Am Soc Nephrol*. 2022;33:1277–1292. <https://doi.org/10.1681/ASN.2021101326>
24. Sharpe D. Chi-square test is statistically significant: now what? *Pract Assess Res Eval*. 20:8. doi: <https://doi.org/10.7275/tbfa-x148>
25. Advanced issues and deeper insights. In: Burnham KP, Anderson DR, eds. *Model Selection and Multimodel Inference*. New York: Springer; 2004:267–351. https://doi.org/10.1007/978-0-387-22456-5_6
26. Vasileiou G, Hoyer J, Thiel CT, et al. Prenatal diagnosis of HNF1B-associated renal cysts: is there a need to differentiate intragenic variants from 17q12 microdeletion syndrome? *Prenat Diagn*. 2019;39:1136–1147. <https://doi.org/10.1002/pd.5556>
27. Hojny J, Bartu M, Kravcova E, et al. Identification of novel HNF1B mRNA splicing variants and their qualitative and semi-quantitative profile in selected healthy and tumour tissues. *Sci Rep*. 2020;10:6958. <https://doi.org/10.1038/s41598-020-63733-x>
28. Barbacci E, Reber M, Ott MO, Breillat C, Huetz F, Cereghini S. Variant hepatocyte nuclear factor 1 is required for visceral endoderm specification. *Development*. 1999;126:4795–4805. <https://doi.org/10.1242/dev.126.21.4795>
29. Niborski LL, Paces-Fessy M, Ricci P, et al. Hnf1b haploinsufficiency differentially affects developmental target genes in a new renal cysts and diabetes mouse model. *Dis Model Mech*. 2021;14:dmm047498. <https://doi.org/10.1242/dmm.047498>
30. Yoshida K, Mushimoto Y, Tanase-Nakao K, et al. A case report with functional characterization of a HNF1B mutation (p.Leu168Pro) causing MODY5. *Clin Pediatr Endocrinol*. 2021;30:179–185. <https://doi.org/10.1297/cpe.30.179>